XBiotech Inc. (XBIT)
NASDAQ: XBIT · Real-Time Price · USD
6.83
+0.21 (3.17%)
Nov 22, 2024, 4:00 PM EST - Market closed
XBiotech Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
82
Market Cap
208.20M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionXBIT News
- 5 months ago - What's Going On With Small-Cap Cancer Focused XBiotech On Tuesday? - Benzinga
- 5 months ago - XBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic Cancer - GlobeNewsWire
- 6 months ago - XBiotech: Several Shots On Goal In Big Target Market Indications - Seeking Alpha
- 11 months ago - XBiotech to Begin Constructing New R&D Facility on its 48-acre Campus - GlobeNewsWire
- 1 year ago - Dr. Alan Kivitz to Chair XBiotech's Natrunix Program in Rheumatoid Arthritis - GlobeNewsWire
- 1 year ago - XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke - GlobeNewsWire
- 1 year ago - XBiotech Announces Enrollment Completion of Phase II, Placebo Controlled, Multicenter Study for Natrunix in Pancreatic Cancer - GlobeNewsWire
- 1 year ago - XBiotech Announces First Patient Begins Novel Natrunix Therapy in Phase II Rheumatoid Arthritis (RA) Clinical Trial - GlobeNewsWire